Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity

BMC Research Notes
Rui TadaYukihiko Aramaki

Abstract

Infectious diseases remain a threat to human life. Vaccination against pathogenic microbes is a primary method of treatment as well as prevention of infectious diseases. Particularly mucosal vaccination is a promising approach to fight against most infectious diseases, because mucosal surfaces are a major point of entry for most pathogens. We recently developed an effective mucosal adjuvant of cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol) (DOTAP/DC-chol liposomes). However, the mechanism(s) underlying the mucosal adjuvant effects exerted by the cationic liposomes have been unclear. In this study, we investigated the role of granulocyte-macrophage colony-stimulating factor (GM-CSF), which was reported to act as a mucosal adjuvant, on the mucosal adjuvant activities of DOTAP/DC-chol liposomes when administered intranasally to mice. Here, we show that, although intranasal vaccination with cationic liposomes in combination with antigenic protein elicited GM-CSF expression at the site of administration, blocking GM-CSF function by using an anti-GM-CSF neutralizing antibody did not alter antigen-specific antibody production induced by DOTAP/D...Continue Reading

References

Jan 1, 1990·International Journal of Cell Cloning·J D GriffinY Kanakura
Dec 16, 1998·Journal of Leukocyte Biology·R EvansS J Kamdar
Mar 31, 2000·Immunologic Research·P N BoyakaJ McGhee
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B Spellberg, J E Edwards
Aug 23, 2001·Advanced Drug Delivery Reviews·P N Boyaka, J R McGhee
Oct 6, 2001·The New England Journal of Medicine·G Ada
Jul 23, 2002·Trends in Immunology·John A Hamilton
Apr 15, 2005·Emerging Infectious Diseases·Anthony S FauciGregory K Folkers
Jan 31, 2006·Nature Immunology·Morgan HuseMark M Davis
Feb 3, 2007·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Jun KunisawaHiroshi Kiyono
Jan 22, 2008·Journal of Agricultural and Food Chemistry·Rui TadaNaohito Ohno
Mar 3, 2010·Annual Review of Immunology·Jinfang ZhuWilliam E Paul
Mar 6, 2010·American Journal of Respiratory and Critical Care Medicine·Ross VlahosGary P Anderson
Mar 12, 2011·Journal of Leukocyte Biology·Maitham KhajahDonna-Marie McCafferty
Aug 10, 2011·Clinical & Developmental Immunology·Afton L Thompson, Herman F Staats
Feb 11, 2012·Journal of Medical Microbiology·Petra Oyston, Karen Robinson
Jul 18, 2012·The Journal of Experimental Medicine·Monique A M WillartHamida Hammad
May 31, 2013·Frontiers in Immunology·Sunita AwateGeorge Mutwiri
May 3, 2014·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hidehiko SuzukiJun Kunisawa
Sep 8, 2015·Current Opinion in Microbiology·Ingrid L ScullyAnnaliesa S Anderson

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
PCR

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.